Abdulafeez Akinloye

Mr. Abdulafeez Akinloye

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Physics of Fluids
Verified
Journal Article
Closed access
PDF file
OAOlatunde Abidakun
Olatunde Abidakun
AAAbdulafeez Akinloye
Abdulafeez Akinloye
Damir ValievDamir Valiev
Damir Valiev
V'yacheslav AkkermanV'yacheslav Akkerman
V'yacheslav Akkerman
The present study scrutinizes premixed flame dynamics in micro-channels, thereby shedding light on advanced miniature micro-combustion technologies. While equidiffusive burning (when the Lewis number Le = 1) is a conventional approach adopted in numerous theoretical studies, real premixed flames are typically non-equidiffusive (Le ≠ 1), which leads to intriguing effects, such as diffusional-thermal instability. An equidiffusive computational study [V. Akkerman et al., Combust. Flame 145, 675–687 (2006)] reported regular oscillations of premixed flames spreading in channels having nonslip walls and open extremes. Here, this investigation is extended to non-equidiffusive combustion in order to systematically study the impact of the Lewis number on the flame in this geometry. The analysis is performed by means of computational simulations of the reacting flow equations with fully-compressible hydrodynamics and one-step Arrhenius chemical kinetics in channels with adiabatic and isothermal walls. In the adiabatic channels, which are the main case of study, it is found that the flames oscillate at low Lewis numbers, with the oscillation frequency decreasing with Le, while for the Le > 1 flames, a tendency to steady flame propagation is observed. The oscillation parameters also depend on the thermal expansion ratio and the channel width, although the impacts are rather quantitative than qualitative. The analysis is subsequently extended to the isothermal channels. It is shown that the role of heat losses to the walls is important and may potentially dominate over that of the Lewis number. At the same time, the impact of Le on burning in the isothermal channels is qualitatively weaker than that in the adiabatic channels.

1 February 2026 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
SAShakir Atoyebi
Shakir Atoyebi
PVPrajith Venkatasubramanian
Prajith Venkatasubramanian
AAAbdulafeez Akinloye
Abdulafeez Akinloye
OEOluwasegun Eniayewu
Oluwasegun Eniayewu
BBBrookie M. Best
Brookie M. Best
AOAdeniyi Olagunju
Adeniyi Olagunju
Model‐informed drug development is increasingly integrated across the drug development continuum, enabling more efficient, cost‐effective, and targeted trials while reducing reliance on animal studies. Achieving pharmacoequity requires not only equitable access to medicines but also to the data and knowledge that inform drug development and regulatory decisions. To address challenges in pharmacokinetic data sharing, PKRxiv ( https://pkrxiv.org/ ) was developed as a discipline‐specific repository designed around Findable, Accessible, Interoperable, Reusable (FAIR) principles. This tutorial introduces PKRxiv’s rationale, design, data submission and access workflows, and practical use cases. Available datasets at the end of September 2025 include over 5,500 individual drug concentration‐time data points from over 900 unique participants across 3 continents. The platform supports structured submission of pharmacokinetic, pharmacogenetic, and safety/efficacy data, with persistent digital object identifiers for discoverability and citation. Contributors can apply one of three data sharing models—unrestricted, noncommercial, or contributor‐controlled—with optional embargo periods. Users can explore datasets using the Data Explorer or Data Cards, or submit requests after providing a statement of intended use case. It enables pooling of datasets across multiple studies. Recommendations to help advance the field are proposed as data sharing becomes more widely expected: obtaining consent for unspecified future research use of data, sharing data underlying peer‐reviewed publications as standard practice, including discipline‐specific repositories in data management plans, and incentivizing post‐approval data sharing by industry. Supporting data from all therapeutic areas and population groups, PKRxiv is a critical step toward a more transparent, equitable, and collaborative future in clinical pharmacology research.

28 September 2026 in Analytical Chemistry
Verified
Journal Article
Closed access
AAAbdulafeez Akinloye
Abdulafeez Akinloye
LDLeigh Donnellan
Leigh Donnellan
PMParul Mittal
Parul Mittal
CYClifford Young
Clifford Young
MNMariam Nassiri
Mariam Nassiri
PHPeter Hoffmann
Peter Hoffmann

22 February 2024 in Future Pharmacology
Verified
Journal Article
Open access
PDF file
AAAbdulafeez Akinloye
Abdulafeez Akinloye
Timothy OyedejiTimothy Oyedeji
Timothy Oyedeji
OEOluwasegun Eniayewu
Oluwasegun Eniayewu
BABabatunde Ayodeji Adeagbo
Babatunde Ayodeji Adeagbo
OBOluseye Bolaji
Oluseye Bolaji
AOAdeniyi Olagunju
Adeniyi Olagunju
Nitazoxanide use is limited by gastrointestinal side effects associated with increasing dose. In this drug repurposing study, we investigated the possibility of enhancing the exposure of its active metabolite, tizoxanide, through pharmacokinetic interaction with atazanavir/ritonavir. In this crossover drug–drug interaction study, 18 healthy participants received a single dose of 1000 mg of nitazoxanide alone and in combination with 300/100 mg atazanavir/ritonavir in period 1 and 2 respectively. On both days, blood samples for intensive pharmacokinetic analyses were collected at 0–12 h post-dose. To explore the utility of dried blood spots (DBS) as an alternative to plasma for tizoxanide quantification, 50 µL of blood from some participants was spotted on DBS cards and correlated with plasma concentrations. Pharmacokinetic parameters were derived by non-compartmental analysis and compared between both periods. Co-administration of nitazoxanide with atazanavir/ritonavir resulted in a significant increase in tizoxanide plasma exposure [GMR (90% CI) of AUC0–12h, Cmax and C12h being 1.872 (1.870–1.875), 2.029 (1.99–2.07) and 3.14 (2.268–4.352), respectively]. DBS concentration (%CV) was 46.3% (5.6%) lower than plasma concentrations, and there was strong correlation (R = 0.95, p < 0.001) between DBS-derived plasma concentration and plasma concentrations. Co-administration with atazanavir/ritonavir enhanced tizoxanide exposure with no report of adverse events in healthy volunteers.

14 July 2026 in ChemRxiv
Verified
Preprint
Open access
AAAbdulafeez Akinloye
Abdulafeez Akinloye
LDLeigh Donnellan
Leigh Donnellan
CYClifford Young
Clifford Young
PMParul Mittal
Parul Mittal
MCMark R. Condina
Mark R. Condina
PHPeter Hoffmann
Peter Hoffmann
Disulphide bonds contribute to the conformational structure of monoclonal antibodies (mAbs) and are therefore vital for their stability, biological function and safety. However, the biopharmaceutical manufacturing process can influence these bonds, potentially leading to the formation of free thiols, scrambled configurations, or degradation products, which may negatively impact quality and safety. Current analytical strategies for characterising disulphide bonds and free thiols in mAbs are predominantly based on labelled and label-free bottom-up mass spectrometry approaches. However, these methods are often time-consuming and may generate unwanted artefacts such as disulphide bond scrambled products. As a result, middle-down and top-down mass spectrometry methods are being explored as alternative approaches. However, their broader application remains limited by challenges in achieving sufficient MS/MS fragmentation for reliable characterisation of protein modifications and disulphide linkages. In this study, we evaluated an electron-activated dissociation (EAD) on the Sciex ZenoTOF 7600+ system for middle-down characterisation of intra- and interchain DSB and free thiols in mAbs. The EAD fragmentation generated diagnostic fragment ion patterns that can confirm intra-chain disulphide linkages on the subunits. This approach was applied to assess domain-specific free thiol on the NISTmAb Fc/2 subunit, as well as disulphide-scrambled products generated from mild reduction. Additionally, the method was effective in characterising fragments from antibody degradation. Overall, this EAD-based approach provides a rapid alternative for antibody product characterisation across different stages of the production process.

13 October 2026 in Journal of Proteome Research
Verified
Journal Article
Closed access
AAAbdulafeez Akinloye
Abdulafeez Akinloye
SRSri Ramarathinam
Sri Ramarathinam
PMParul Mittal
Parul Mittal
DPDaniel Pincher
Daniel Pincher
LDLeigh Donnellan
Leigh Donnellan
PHPeter Hoffmann
Peter Hoffmann